About NeOnc Technologies Holdings Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://neonc.com
Frequently Asked Questions
What is the 52-week range for NTHI?
The 52-week high is $12.99 and the 52-week low is $2.95.
What is the P/E ratio for NTHI?
The P/E ratio data is currently unavailable.
What is the dividend yield for NTHI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
ROE data is currently unavailable.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -48876.25%.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Analyst Recommendation Trends
Wall Street analyst consensus for NTHI over the last few months:
Latest NTHI News
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212. The meeting is scheduled to take place at FDA’s White Oak campus in Silver Spring, Maryland. The Company plans to seek FDA feedback on its NEO212 clinical development program, including an update to its proposed patient population, trial design, endpoints, dose selection and evidence needed to support a future marketing application.
NeOnc Technologies Schedules FDA In-Person End-of-Phase 1 Type B Meeting Concerning NEO212 For November 17
The Company plans to seek FDA feedback on its NEO212 clinical development program, including an update to its proposed patient population, trial design, endpoints, dose selection and evidence needed to support a future
Roth Capital Initiates Coverage On NeOnc Technologies Hldgs with Buy Rating, Announces Price Target of $20
Roth Capital analyst Jonathan Aschoff initiates coverage on NeOnc Technologies Hldgs (NASDAQ:NTHI) with a Buy rating and announces Price Target of $20.
NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has redeemed for cash all 6,000 outstanding shares of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) at their aggregate stated value of $6.0 million. Following the redemption, no shares of Series A Preferred Stock remain outstanding.
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Executive Chairman, President and Chief Executive Officer Amir F. Heshmatpour purchased an additional 35,000 shares of NeOnc common stock in the open market on September 15, 2026, for approximately $115,400, at a weighted average price of approximately $3.30 per share, as will be reported in a Form 4 filed with the U.S. Securities and Exchange Commission (SEC). The purchase follows the Company's $15 million registered direct offering announced on September 9, 2026, and extends a series of open-market purchases by NeOnc's senior leadership since the Company reported positive topline Phase 2a results for intranasal NEO100™ on August 12, 2026.
NeOnc Announces Executive Chairman, President And CEO Amir Heshmatpour Purchases Additional 35K Of Company Shares For ~$115,400, At Weighted Average Price Of ~$3.30/Shr
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers,
NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors
The gross proceeds to the Company from the registered direct offering are estimated to be approximately $15 million before deducting the placement agent’s fees and other estimated offering expenses. The offering is expected to close on or about September 10, 2026, subject to the satisfaction of customary closing conditions.
NeOnc Technologies Enters $15M Securities Purchase Agreements In At‑The‑Market Offering
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers,
BTIG Reiterates Buy on NeOnc Technologies Hldgs, Maintains $15 Price Target
BTIG analyst Thomas Shrader reiterates NeOnc Technologies Hldgs (NASDAQ:NTHI) with a Buy and maintains $15 price target.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | GARNETT KEITHLY | +5,000 | $3.3618 | $16,809 |
| 2026-09-15 | Heshmatpour Amir F | +35,000 | $3.297 | $115,395 |
| 2026-09-14 | CHEN THOMAS C | +5,242 | $3.815 | $19,998 |
| 2026-09-14 | GARNETT KEITHLY | +257 | $3.8948 | $1,001 |
| 2026-09-14 | Heshmatpour Amir F | +15,000 | $3.96 | $59,400 |
| 2026-09-11 | CHEN THOMAS C | +5,556 | $3.6 | $20,002 |
| 2026-09-11 | Heshmatpour Amir F | +37,000 | $3.6654 | $135,620 |
| 2026-08-18 | CHEN THOMAS C | +12,757 | $5.487 | $69,998 |
| 2026-08-18 | Heshmatpour Amir F | +9,000 | $5.54 | $49,860 |
| 2026-08-17 | CHEN THOMAS C | +2,472 | $4.0445 | $9,998 |
| 2026-08-17 | CHEN THOMAS C | +2,472 | $4.0445 | $9,998 |
| 2026-08-17 | Heshmatpour Amir F | +3,000 | $4.3733 | $13,120 |
| 2026-08-14 | CHEN THOMAS C | +33,787 | $3.8477 | $130,002 |
| 2026-08-14 | CHEN THOMAS C | +33,787 | $3.8477 | $130,002 |
| 2026-08-14 | Heshmatpour Amir F | +12,000 | $3.7883 | $45,460 |
| 2026-07-10 | SHOMALI NASIM | +50,000 | - | - |
| 2026-05-01 | Heshmatpour Amir F | +10,000 | $4.1592 | $41,592 |
| 2026-04-28 | Heshmatpour Amir F | +10,000 | $4.518 | $45,180 |
| 2026-04-24 | CHEN THOMAS C | +10,000 | $4.8 | $48,000 |
| 2026-04-23 | Neman-Ebrahim Yousha | +500 | $4.88 | $2,440 |
| 2026-04-23 | Heshmatpour Amir F | +10,000 | $4.9 | $49,000 |
| 2026-04-10 | CHEN THOMAS C | +948 | $5.1677 | $4,899 |
| 2026-04-10 | Heshmatpour Amir F | +10,000 | $4.895 | $48,950 |
| 2026-04-09 | SUH, DAVID JR. | +200 | $5 | $1,000 |
| 2026-04-09 | Heshmatpour Amir F | +5,000 | $5.19 | $25,950 |
| 2026-04-08 | Heshmatpour Amir F | +10,000 | $5.605 | $56,050 |
| 2026-04-06 | Heshmatpour Amir F | +5,000 | $6.32 | $31,600 |
| 2026-04-02 | Heshmatpour Amir F | +20,000 | $6.0899 | $121,798 |
| 2026-03-01 | SUH, DAVID JR. | +58,334 | - | - |
| 2026-03-01 | SUH, DAVID JR. | +111,666 | - | - |
| 2025-11-24 | Heshmatpour Amir F | +6,000 | $6.51 | $39,060 |
| 2025-11-21 | Heshmatpour Amir F | +4,000 | $6.5 | $26,000 |
| 2025-11-21 | Heshmatpour Amir F | +20,000 | $5.98 | $119,600 |
| 2025-11-20 | Neman-Ebrahim Yousha | +1,100 | $6.69 | $7,359 |
| 2025-11-06 | Heshmatpour Amir F | +1,200,000 | - | - |